Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions

Expert Review of Anticancer Therapy
Chau T Dang

Abstract

Adjuvant chemotherapy with anthracycline-based regimens has been proven to decrease the risk of relapse and cancer-related mortality in women with early-stage breast cancer. The taxanes, paclitaxel and docetaxel, have been incorporated into several adjuvant chemotherapy regimens in recent studies. Some of these trials have matured and demonstrated a definitive benefit with the use of taxanes. The available studies reveal that the addition of a taxane after an anthracycline or the substitution of a taxane into a three-drug regimen, such as docetaxel, doxorubicin and cyclophosphamide, clearly demonstrate a benefit for taxanes in the adjuvant treatment of breast cancer. The toxicities of the taxanes are generally acceptable. Targeted therapy, such as with trastuzumab, has demonstrated a large benefit that previously has never been seen in adjuvant chemotherapy trials, and thus, should now be part of the standard in the treatment of HER-2/neu positive breast cancer. Newer agents are on the horizon.

References

Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J JassemUNKNOWN Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group
Nov 19, 2002·Clinical Breast Cancer·Steven D HeysUNKNOWN Aberdeen Breast Group
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Marc NabholtzUNKNOWN TAX 306 Study Group
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
Nov 13, 2004·Breast Cancer Research and Treatment·Reju KorahRobert Wieder
Nov 13, 2004·Breast Cancer Research and Treatment·Hideya TakeuchiYoshihiko Maehara
Mar 17, 2005·Breast Cancer Research and Treatment·Susana M Campos
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators
Aug 6, 2005·Molecular and Cellular Neurosciences·Pavel ItsyksonBenjamin E Reubinoff
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marjorie C GreenGabriel N Hortobagyi
Sep 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark

❮ Previous
Next ❯

Citations

Dec 15, 2010·Journal of Immunotherapy·Erik E JohnsonAlexander L Rakhmilevich
May 24, 2006·BMC Public Health·Paul D JamesYang Mao
Oct 25, 2014·Journal of Cancer Survivorship : Research and Practice·Angel QinPaula Silverman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.